A Phase 3 interventional study of Placebo and Izokibep in Hidradenitis Suppurativa, sponsored by ACELYRIN Inc.. Terminated at 98 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-15.
Sponsored by ACELYRIN Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Hidradenitis Suppurativa with a site in United States — 39 open to participants now, 56 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 162 studies in Hidradenitis Suppurativa with a site in United States, this one is the 24th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2023, is one of 24 in phase 3, and was the 103rd registered.
286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.
Browse Hidradenitis Suppurativa studies →39 of the 162 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Integra LifeSciences Corporation · Sites in United States
Ages 21+
Spyre Therapeutics, Inc. · Sites in United States, Canada
Ages 18–75
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 13 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 258 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 23 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 162 have an industry lead sponsor. The 10 most frequent:
ACELYRIN Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
ACELYRIN Inc. has 2 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 162 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in participants with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve participants, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General
Type of Participant and Disease Characteristics
Exclusion Criteria:
Medical Conditions
Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo as a subcutaneous (SC) injection every week (QW) from Day 1 to Week 15. Participants will then receive izokibep as a SC injection QW from Week 16 to Week 51.
Drug: Placebo · Drug: Izokibep
Participants will receive izokibep QW from Day 1 to Week 51.
Drug: Izokibep
Solution for injection
Solution for injection
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 12
The percentage of participants achieving HiSCR75 was defined as meeting all 3 criteria below: * (\[abscess and inflammatory nodule (AN) count at baseline - AN count at current visit\] / AN count at baseline) × 100% ≥ 75% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR75 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
Time frame: Week 12
Percentage of Participants Achieving HiSCR90 at Week 12
The percentage of participants achieving HiSCR90 was defined as meeting all 3 criteria below: * (\[AN count at baseline - AN count at current visit\] / AN count at baseline) × 100% ≥ 90% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR90 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
Time frame: Week 12
Percentage of Participants Achieving HiSCR100 at Week 12
The percentage of participants achieving HiSCR100 was defined as meeting all 3 criteria below: * (\[AN count at baseline - AN count at current visit\] / AN count at baseline) × 100% = 100% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR100 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
Time frame: Week 12
Percentage of Participants Achieving HiSCR50 at Week 12
The percentage of participants achieving HiSCR50 was defined as meeting all 3 criteria below: * \[(AN count at baseline - AN count at current visit) / AN count at baseline\] × 100% ≥ 50% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR50 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
Time frame: Week 12
Percentage of Participants Who Experienced One or More (≥ 1) Disease Flare at Week 12
HS flares were defined as ≥ 25% increase in AN count with a minimum increase of 2 AN relative to baseline, i.e. participants must meet all the following criteria: * (AN count at current visit- AN count at baseline) / AN count at baseline ×100% ≥ 25% * AN count at current visit- AN count at baseline ≥ 2. Participants who received antibiotic therapy that could affect HS were imputed as non-response (NRI). Other participants with missing data were imputed with multiple imputation.
Time frame: Up to Week 12
Change From Baseline in Dermatology Life Quality Index (DLQI)
DLQI included 10 items arranged in 6 categories: symptoms and feelings, daily activity, leisure, work or study, interpersonal relationships, and treatment. The total score could range from 0 (no impact to life quality) to 30 (maximum impact).
Time frame: Baseline and Week 12
Percentage of Participants With Baseline Hurley Stage II Who Achieved AN Count of 0, 1, or 2 at Week 12
Calculated as observed values of 0, 1, or 2 for AN count (abscess count + inflammatory nodule count). AN count of 0, 1, or 2 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
Time frame: Week 12
Percentage of Participants With Baseline NRS ≥ 4 Achieving at Least 3-point Reduction at Week 12 in Numeric Rating Scale (NRS) Patient Global Assessment of Skin Pain at Its Worst
NRS in Patient Global Assessment of Skin Pain ranged from 0 (no skin pain) to 10 (skin pain bad as you can imagine). The skin pain score at each visit was calculated using average of daily scores among the 7 days up to and including the day of visit, with a minimum of 4 days (consecutive or non-consecutive) with scores required. Reduction in NRS was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
Time frame: Week 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and Adverse Event of Special Interest (AESIs) in Period 1
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. The following events of special interest were monitored in this study: candida infection; inflammatory bowel disease (IBD); suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events; tuberculosis; infections; cytopenias and systemic hypersensitivity reactions. Clinically significant changes in vital signs and laboratory tests recorded after treatment administration were documented as TEAEs.
Time frame: Up to Week 16
Number of Participants With TEAEs, SAEs and AESIs in Period 2
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. The following events of special interest were monitored in this study: candida infection; IBD; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events; tuberculosis; infections; cytopenias and systemic hypersensitivity reactions. Clinically significant changes in vital signs and laboratory tests recorded after treatment administration were documented as TEAEs.
Time frame: From Week 16 to follow-up, Week 59
A total of 258 participants were enrolled in Canada, France, Germany, Japan, Poland, Spain and the United States from June 2023 to January 2025. Participants were randomized to receive izokibep or placebo once weekly (QW) until Week 15 (Period 1). Then, all participants received izokibep QW from Week 16 until Week 51 (Period 2). The Sponsor decided to terminate the study early after all participants completed (or discontinued) treatment at Week 32.
| Milestone | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| Started | 129 | 129 |
| Completed period 1 | 109 | 103 |
| Completed | 19 | 9 |
| Not completed | 110 | 120 |
| Withdrew: Lost to follow-up | 12 | 18 |
| Withdrew: Withdrawal by subject | 29 | 37 |
| Withdrew: Decision by sponsor | 69 | 65 |
The percentage of participants achieving HiSCR75 was defined as meeting all 3 criteria below: * (\[abscess and inflammatory nodule (AN) count at baseline - AN count at current visit\] / AN count at baseline) × 100% ≥ 75% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR75 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
| percentage of participants | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 12 | 20.3 (13.1 to 27.6) | 32.6 (24.3 to 40.9) |
The percentage of participants achieving HiSCR90 was defined as meeting all 3 criteria below: * (\[AN count at baseline - AN count at current visit\] / AN count at baseline) × 100% ≥ 90% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR90 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
| percentage of participants | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| Percentage of Participants Achieving HiSCR90 at Week 12 | 9.2 (3.8 to 14.5) | 24.3 (16.7 to 31.9) |
The percentage of participants achieving HiSCR100 was defined as meeting all 3 criteria below: * (\[AN count at baseline - AN count at current visit\] / AN count at baseline) × 100% = 100% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR100 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
| percentage of participants | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| Percentage of Participants Achieving HiSCR100 at Week 12 | 7.3 (2.5 to 12.2) | 21.4 (14.2 to 28.7) |
The percentage of participants achieving HiSCR50 was defined as meeting all 3 criteria below: * \[(AN count at baseline - AN count at current visit) / AN count at baseline\] × 100% ≥ 50% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR50 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
| percentage of participants | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| Percentage of Participants Achieving HiSCR50 at Week 12 | 36.5 (27.8 to 45.2) | 47.9 (39.0 to 56.8) |
HS flares were defined as ≥ 25% increase in AN count with a minimum increase of 2 AN relative to baseline, i.e. participants must meet all the following criteria: * (AN count at current visit- AN count at baseline) / AN count at baseline ×100% ≥ 25% * AN count at current visit- AN count at baseline ≥ 2. Participants who received antibiotic therapy that could affect HS were imputed as non-response (NRI). Other participants with missing data were imputed with multiple imputation.
| percentage of participants | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| Percentage of Participants Who Experienced One or More (≥ 1) Disease Flare at Week 12 | 31.1 (22.9 to 39.3) | 28.3 (20.5 to 36.2) |
DLQI included 10 items arranged in 6 categories: symptoms and feelings, daily activity, leisure, work or study, interpersonal relationships, and treatment. The total score could range from 0 (no impact to life quality) to 30 (maximum impact).
| Score on scale | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) | -2.71 ± 0.519 | -4.87 ± 0.536 |
Calculated as observed values of 0, 1, or 2 for AN count (abscess count + inflammatory nodule count). AN count of 0, 1, or 2 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
| percentage of participants | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| Percentage of Participants With Baseline Hurley Stage II Who Achieved AN Count of 0, 1, or 2 at Week 12 | 25.0 (15.2 to 34.8) | 49.5 (38.1 to 61.0) |
NRS in Patient Global Assessment of Skin Pain ranged from 0 (no skin pain) to 10 (skin pain bad as you can imagine). The skin pain score at each visit was calculated using average of daily scores among the 7 days up to and including the day of visit, with a minimum of 4 days (consecutive or non-consecutive) with scores required. Reduction in NRS was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.
| Percentage of participants | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| Percentage of Participants With Baseline NRS ≥ 4 Achieving at Least 3-point Reduction at Week 12 in Numeric Rating Scale (NRS) Patient Global Assessment of Skin Pain at Its Worst | 17.2 (8.4 to 25.9) | 33.5 (22.1 to 44.8) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. The following events of special interest were monitored in this study: candida infection; inflammatory bowel disease (IBD); suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events; tuberculosis; infections; cytopenias and systemic hypersensitivity reactions. Clinically significant changes in vital signs and laboratory tests recorded after treatment administration were documented as TEAEs.
| Participants | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| TEAEs | 76 | 107 |
| SAEs | 5 | 1 |
| AESIs | 3 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. The following events of special interest were monitored in this study: candida infection; IBD; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events; tuberculosis; infections; cytopenias and systemic hypersensitivity reactions. Clinically significant changes in vital signs and laboratory tests recorded after treatment administration were documented as TEAEs.
| Participants | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW |
|---|---|---|
| TEAEs | 87 | 66 |
| SAEs | 3 | 4 |
| AESIs | 5 | 1 |
Collected over From Screening (Day -28) to Follow-up (Week 59), up to approximately 63 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo QW - Izokibep 160 mg QW: Period 1 | 0/129 (0%) | 5/129 (3.9%) | 35/129 (27.1%) |
| Izokibep 160 mg QW: Period 1 | 0/129 (0%) | 1/129 (0.8%) | 93/129 (72.1%) |
| Placebo QW - Izokibep 160 mg QW: Period 2 | 0/109 (0%) | 3/109 (2.8%) | 69/109 (63.3%) |
| Izokibep 160 mg QW: Period 2 | 0/100 (0%) | 4/100 (4%) | 40/100 (40%) |
| Event | Placebo QW - Izokibep 160 mg QW: Period 1 | Izokibep 160 mg QW: Period 1 | Placebo QW - Izokibep 160 mg QW: Period 2 | Izokibep 160 mg QW: Period 2 |
|---|---|---|---|---|
| HidradenitisSkin and subcutaneous tissue disorders | 1/129 | 0/129 | 0/109 | 1/100 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/129 | 0/129 | 0/109 | 1/100 |
| Spinal stenosisMusculoskeletal and connective tissue disorders | 0/129 | 0/129 | 0/109 | 1/100 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/129 | 0/129 | 0/109 | 1/100 |
| Eye disorderEye disorders | 0/129 | 0/129 | 0/109 | 1/100 |
| Hepatic enzyme increasedInvestigations | 1/129 | 0/129 | 1/109 | 0/100 |
| Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/129 | 0/129 | 1/109 | 0/100 |
| CellulitisInfections and infestations | 0/129 | 0/129 | 1/109 | 0/100 |
| Pelvic fractureInjury, poisoning and procedural complications | 1/129 | 0/129 | 0/109 | 0/100 |
| Post procedural complicationInjury, poisoning and procedural complications | 1/129 | 0/129 | 0/109 | 0/100 |
| Event | Placebo QW - Izokibep 160 mg QW: Period 1 | Izokibep 160 mg QW: Period 1 | Placebo QW - Izokibep 160 mg QW: Period 2 | Izokibep 160 mg QW: Period 2 |
|---|---|---|---|---|
| Injection site reactionGeneral disorders | 10/129 | 86/129 | 66/109 | 34/100 |
| HeadacheNervous system disorders | 16/129 | 14/129 | 2/109 | 5/100 |
| NasopharyngitisInfections and infestations | 9/129 | 11/129 | 5/109 | 8/100 |
| FatigueGeneral disorders | 3/129 | 7/129 | 0/109 | 2/100 |
| Upper respiratory tract infectionInfections and infestations | 5/129 | 7/129 | 5/109 | 4/100 |
| DiarrhoeaGastrointestinal disorders | 2/129 | 7/129 | 0/109 | 0/100 |
| Age, Categorical(Participants) | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 125 | 127 | 252 |
| >=65 years | 4 | 2 | 6 |
| Age, Continuous(years) | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW | Total |
|---|---|---|---|
| Mean | 37.4 ± 12.85 | 37.1 ± 11.89 | 37.3 ± 12.35 |
| Sex: Female, Male(Participants) | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW | Total |
|---|---|---|---|
| Female | 89 | 89 | 178 |
| Male | 40 | 40 | 80 |
| Ethnicity (NIH/OMB)(Participants) | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 12 | 30 |
| Not Hispanic or Latino | 108 | 115 | 223 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race/Ethnicity, Customized(Participants) | Placebo-Izokibep 160 mg QW | Izokibep 160 mg QW | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 3 |
| Asian | 10 | 8 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 28 | 21 | 49 |
| White | 90 | 91 | 181 |
| More than one race | 0 | 0 | 0 |
| Other | 1 | 5 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2023 to primary completion in Jul 2024, 13 months.
Results were first posted in Oct 2025, 1 year 2 months after primary completion. A results delay was requested in Apr 2025.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Izokibep
ACELYRIN Inc.